[Code of Federal Regulations]

[Title 42, Volume 2]

[Revised as of October 1, 2005]

From the U.S. Government Printing Office via GPO Access

[CITE: 42CFR410.39]



[Page 337]

 

                         TITLE 42--PUBLIC HEALTH

 

                    CHAPTER IV--CENTERS FOR MEDICARE

                          & MEDICAID SERVICES,

                        DEPARTMENT OF HEALTH AND

                             HUMAN SERVICES

 

PART 410_SUPPLEMENTARY MEDICAL INSURANCE (SMI) BENEFITS--Table of Contents

 

               Subpart B_Medical and Other Health Services

 

Sec. 410.39  Prostate cancer screening tests: Conditions for and 

limitations on coverage.



    (a) Definitions. As used in this section, the following definitions 

apply:

    (1) Prostate cancer screening tests means any of the following 

procedures furnished to an individual for the purpose of early detection 

of prostate cancer:

    (i) A screening digital rectal examination.

    (ii) A screening prostate-specific antigen blood test.

    (iii) For years beginning after 2002, other procedures CMS finds 

appropriate for the purpose of early detection of prostate cancer, 

taking into account changes in technology and standards of medical 

practice, availability, effectiveness, costs, and other factors CMS 

considers appropriate.

    (2) A screening digital rectal examination means a clinical 

examination of an individual's prostate for nodules or other 

abnormalities of the prostate.

    (3) A screening prostate-specific antigen blood test means a test 

that measures the level of prostate-specific antigen in an individual's 

blood.

    (4) A physician for purposes of this provision means a doctor of 

medicine or osteopathy (as defined in section 1861(r)(1) of the Act) who 

is fully knowledgeable about the beneficiary, and who would be 

responsible for explaining the results of the screening examination or 

test.

    (5) A physician assistant, nurse practitioner, clinical nurse 

specialist, or certified nurse midwife for purposes of this provision 

means a physician assistant, nurse practitioner, clinical nurse 

specialist, or certified nurse midwife (as defined in sections 1861(aa) 

and 1861(gg) of the Act) who is fully knowledgeable about the 

beneficiary, and who would be responsible for explaining the results of 

the screening examination or test.

    (b) Condition for coverage of screening digital rectal examinations. 

Medicare Part B pays for a screening digital rectal examination if it is 

performed by the beneficiary's physician, or by the beneficiary's 

physician assistant, nurse practitioner, clinical nurse specialist, or 

certified nurse midwife as defined in paragraphs (a)(4) or (a)(5) of 

this section who is authorized to perform this service under State law.

    (c) Limitation on coverage of screening digital rectal examinations. 

(1) Payment may not be made for a screening digital rectal examination 

performed for a man age 50 or younger.

    (2) For an individual over 50 years of age, payment may be made for 

a screening digital rectal examination only if the man has not had such 

an examination paid for by Medicare during the preceding 11 months 

following the month in which his last Medicare-covered screening digital 

rectal examination was performed.

    (d) Condition for coverage of screening prostate-specific antigen 

blood tests. Medicare Part B pays for a screening prostate-specific 

antigen blood test if it is ordered by the beneficiary's physician, or 

by the beneficiary's physician assistant, nurse practitioner, clinical 

nurse specialist, or certified nurse midwife as defined in paragraphs 

(a)(4) or (a)(5) of this section who is authorized to order this test 

under State law.

    (e) Limitation on coverage of screening prostate-specific antigen 

blood test. (1) Payment may not be made for a screening prostate-

specific antigen blood test performed for a man age 50 or younger.

    (2) For an individual over 50 years of age, payment may be made for 

a screening prostate-specific antigen blood test only if the man has not 

had such an examination paid for by Medicare during the preceding 11 

months following the month in which his last Medicare-covered screening 

prostate-specific antigen blood test was performed.



[64 FR 59440, Nov. 2, 1999, as amended at 65 FR 19331, Apr. 11, 2000]